Contineum Therapeutics, Inc. (CTNM) · Sep 14, 2026 · Other events

Contineum’s PIPE-307 misses MDD trial endpoint as J&J weighs next steps

Below the bar — Primary efficacy endpoint not achieved

Contineum’s partnered depression drug failed its Phase 2 efficacy test. J&J is reviewing exploratory data before deciding whether to continue.

Contineum is a clinical-stage biotech whose central near-term value rests on advancing wholly owned PIPE-791 in Phase 2 IPF, while Johnson & Johnson develops partnered PIPE-307 for major depressive disorder. Its Q2 update had already said MOONLIGHT-1 enrollment was complete, and company materials had pointed to a 2026 readout, so the timing was partly known; the efficacy result was not.

The depression program failed the trial’s key test. MOONLIGHT-1 did not show the required improvement in MADRS depression scores versus placebo at Day 5. 〔0〕 That is a below-the-bar clinical readout, not merely a mixed safety update: tolerability was acceptable, but the study did not establish early antidepressant efficacy. 〔1〕

PIPE-307 is now dependent on a salvageable secondary signal. Johnson & Johnson is still reviewing prespecified exploratory endpoints and the overall clinical relevance of the data before deciding what comes next. 〔2〕 That leaves a possibility of continued development, but the primary result removes the clean proof-of-concept case the program needed.

The setback is concentrated in the partnered asset, not the lead IPF program. Contineum’s remaining core story is PIPE-791, its LPA1 antagonist being advanced in a global Phase 2 IPF trial, while PIPE-307’s MDD development is controlled at J&J’s discretion. The company’s pipeline identifies PIPE-791 as its lead IPF program and PIPE-307 as a J&J-licensed MDD asset. 〔3〕

Bottom line: This is a meaningful negative clinical update because PIPE-307 missed its primary efficacy endpoint, leaving J&J to determine whether exploratory data justify further work. It does not erase Contineum’s IPF program, but it removes one important partnered path to value unless the follow-on analysis changes the interpretation.

What to watch next

J&J decision on exploratory data and PIPE-307 next steps

Original filing on SEC EDGAR

More Contineum Therapeutics, Inc. news

Contineum’s PIPE-307 misses MDD trial endpoint as J&J weighs next steps | CTNM Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.